Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2010 13:31 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502

BUFFALO, NY--(Marketwire - January 19, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the first healthy volunteers have been dosed in the second human safety study for CBLB502, a...
January 12, 2010 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure

BUFFALO, NY--(Marketwire - January 12, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it intends to respond to a Request for Proposal (RFP) recently issued by The Department of...
January 06, 2010 09:49 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Receives First U.S. Patent for Radiation Protection Drug CBLB502

BUFFALO, NY--(Marketwire - January 6, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled "Modulating...
January 05, 2010 09:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at OneMedForum

BUFFALO, NY--(Marketwire - January 5, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the OneMedForum 2010, January 12-13, in San Francisco,...
December 30, 2009 11:26 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Establishes Joint Venture to Develop Curaxin Compounds for Cancer Applications

BUFFALO, NY--(Marketwire - December 30, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has formally entered into a 50/50 joint venture, Incuron, with Bioprocess Capital...
December 22, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs President and CEO Reports Progress on Clinical and Corporate Developments

BUFFALO, NY--(Marketwire - December 22, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today issued a statement from its President and CEO, Michael Fonstein, Ph.D., providing an update on clinical...
November 23, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Opens Enrollment of Second Safety Study for CBLB502

BUFFALO, NY--(Marketwire - November 23, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the opening of enrollment for the second human safety study for CBLB502, a drug under...
November 18, 2009 09:28 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential

BUFFALO, NY--(Marketwire - November 18, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a breakthrough discovery into the mechanism of action of the Company's first generation...
November 02, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at Merriman 6th Annual Investor Summit

BUFFALO, NY--(Marketwire - November 2, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Merriman Curhan Ford 6th Annual Investor Summit,...
October 20, 2009 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Host Roundtable on Protectan CBLB502 for Acute Radiation Syndrome

BUFFALO, NY--(Marketwire - October 20, 2009) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will host a roundtable event to discuss Protectan CBLB502, a compound under...